The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
about
Interventions for preventing bone disease in kidney transplant recipientsManagement of mineral and bone disorder after kidney transplantation.The effects of discontinuing cinacalcet at the time of kidney transplantation.Physiology and pathophysiology of the calcium-sensing receptor in the kidneyPharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.The effect of cinacalcet on intraoperative findings in tertiary hyperparathyroidism patients undergoing parathyroidectomyVitamin D and cinacalcet administration pre-transplantation predict hypercalcaemic hyperparathyroidism post-transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years.Photoactive assemblies of organic compounds and biomolecules: drug-protein supramolecular systems.Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantationCKD-MBD after kidney transplantationPotential future uses of calcimimetics in patients with chronic kidney disease.New concepts in calcium-sensing receptor pharmacology and signallingParathyroidectomy is underused in patients with tertiary hyperparathyroidism after renal transplantationMedical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs.The role of calcimimetics in the treatment of hyperparathyroidism.Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.New options for the management of hyperparathyroidism after renal transplantation.Impact of post-kidney transplant parathyroidectomy on allograft function.Therapeutic management of post-kidney transplant hyperparathyroidism.Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic.Clinical utilization of cinacalcet in hypercalcemic conditions.Pharmacotherapy of chronic kidney disease and mineral bone disorder.Cinacalcet hydrochloride for the treatment of hyperparathyroidism.The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities.Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.Phosphate and FGF-23 homeostasis after kidney transplantation.Systematic review of surgical and medical treatment for tertiary hyperparathyroidism.Clinical impact of hypercalcemia in kidney transplant.Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study.Renal transplant and secondary hyperparathyroidism.Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure.Cinacalcet effect on polymorphonuclear leucocytes of kidney transplant patients.Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation.Myelofibrosis-Induced Erythropoietin-Resistant Anemia Due to Severe Refractory Hyperparathyroidism.
P2860
Q24243851-8F0E2E8A-9BAF-403C-9ED8-9EC5E12291EFQ30418461-AD4B4BA6-2B60-465D-BBF6-C0725591EEABQ33597429-E9EB4BB0-C694-486C-88BC-CA9776203D28Q33727776-C110EE71-2D86-4FC5-861D-7836E4E60C5AQ34589090-652EB233-EDA1-48C1-B18A-C6DF68F32A9AQ34626324-8548AFD4-1D78-45D0-9FE9-46451485181FQ34984752-85FF3426-0A5C-447B-A4F7-BE9C5AD2BF28Q35123150-DC2BE9DB-75B6-4FB6-A452-FD62F0E50059Q35226929-47DCF4A5-C5FF-438A-BC06-1D1CA9B12FFCQ35463999-8964621B-D0F0-4F10-A310-44CD02EA6C9FQ35573650-863ECA3D-66F3-4E33-A632-00E7FF7D4A67Q35657894-4D4C900C-F9CF-4125-9E23-957BF2B24ECEQ36395856-11C436E6-B39F-4590-A7BB-FCBD96F92935Q36632228-9347771E-DD84-400F-8FD3-1CA37DC74205Q37013105-50F54791-221D-47F4-8451-3D61D7DE71B7Q37095019-7149CDFB-FF88-4F76-8924-91E06E5C6154Q37111857-0CBF8F7F-DA98-4D32-B093-CC744FA8724BQ37195458-62B6E5BB-B6AB-4BF3-9145-6C44189D88B8Q37599000-012E22F4-5EAB-4E34-90AD-C45C88D321BFQ37767247-41BA0365-A8FB-4421-B07D-1CDD593AC874Q37820101-35701644-F036-4784-A3F0-055CA2A7A663Q37848439-FCABD195-BF5A-44B5-962F-C5C2324BBE57Q37948105-5C1880D2-237E-4608-B995-A1B9CEC90185Q38085702-DE993537-AFF1-441F-BFB3-10D13264B530Q38370743-103149A2-9541-4761-8184-1A042B496477Q38452732-3B7080E9-90FA-453C-9AC5-768F0BDFC0E1Q38576402-0C10E349-666F-4977-BD21-88A03B475BD7Q38594874-80DF7749-9A7C-4458-867D-AE2C090D2B99Q39314892-DA026645-34EA-454E-9A8B-27F97CAA45B2Q39728456-31276606-42FF-4DC3-8695-E7BAD269C60BQ46587079-CD3A2E8A-6C45-4B9B-8901-90452A258261Q46873706-065BF4E0-8369-48BE-8F3E-79E3D51509B3Q50930225-266CA4BC-7EBF-40F3-9562-08E282CD295DQ51909974-5ACEEC5F-278C-4E3F-96E6-FEB73B1BD1F9Q53115117-A33D0E5A-77B3-4838-9D5C-B018C293AFC0Q54481006-28B78C38-3E8E-4791-AD7E-BD8712D47637Q55509850-AC8EA7CB-5A10-4D37-BDC9-48DC1FA028AF
P2860
The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The calcimimetic cinacalcet no ...... ersistent hyperparathyroidism.
@en
The calcimimetic cinacalcet no ...... ersistent hyperparathyroidism.
@nl
type
label
The calcimimetic cinacalcet no ...... ersistent hyperparathyroidism.
@en
The calcimimetic cinacalcet no ...... ersistent hyperparathyroidism.
@nl
prefLabel
The calcimimetic cinacalcet no ...... ersistent hyperparathyroidism.
@en
The calcimimetic cinacalcet no ...... ersistent hyperparathyroidism.
@nl
P2093
P2860
P356
P1476
The calcimimetic cinacalcet no ...... ersistent hyperparathyroidism.
@en
P2093
Anja E Kruse
Felix J Frey
Markus G Mohaupt
P2860
P304
P356
10.1093/NDT/GFH924
P407
P577
2005-06-07T00:00:00Z